Biogen stock (NASDAQ: BIIB) falls 8.2%: Can diranersen recover in Phase 3?

Biogen Inc. (NASDAQ: BIIB) develops therapies for neurological, neurodegenerative and rare diseases, with marketed products spanning Alzheimer’s disease, multiple sclerosis and other specialist categories. Biogen stock closed at US$191.95 on July 14, 2026, falling 8.2% after investors examined detailed Phase 2 CELIA results for the experimental Alzheimer’s therapy diranersen. The study produced strong tau reductions and encouraging results at its lowest dose, but it failed its primary dose-response objective because higher doses performed less convincingly. Biogen’s July 29 earnings report is the next confirmed catalyst, followed by regulatory discussions that will determine how the company advances diranersen into Phase 3.

Why did Biogen stock fall 8.2% after the detailed Phase 2 CELIA presentation?

The July 14 decline reflected a gap between the most encouraging diranersen results and the overall structure of the trial. Biogen had previously disclosed that CELIA did not meet its primary endpoint, but the detailed presentation at the Alzheimer’s Association International Conference gave investors a clearer view of the uneven dose response.

The 60 mg dose administered every six months produced the strongest clinical results. Patients receiving that regimen experienced a 0.54-point, or 26%, slowing of decline on the Clinical Dementia Rating-Sum of Boxes scale compared with placebo after 76 weeks. However, the 115 mg dose administered every six months produced a 14% slowing, while the same dose given every three months produced only a 9% slowing.

That pattern raised questions about whether the benefit at 60 mg represents a durable treatment effect or a result that will prove difficult to reproduce in a larger trial. Trading volume reached approximately 3.9 million shares, more than three times Biogen’s recent average, suggesting the decline reflected a meaningful reassessment rather than routine volatility.

The stock is now down approximately 6.7% over five trading sessions and 4.0% over one month. Its 52-week range extends from US$121.05 to US$219.72, leaving the shares about 12.6% below their annual high but still substantially above their annual low.

What did the lowest diranersen dose show across cognition and Alzheimer’s biomarkers?

Diranersen, previously known as BIIB080, is an antisense oligonucleotide designed to reduce the production of tau protein. Abnormal tau accumulation is closely associated with the progression of Alzheimer’s disease, making tau an important but still unproven therapeutic target.

The 60 mg group showed consistent numerical benefits across several cognitive and composite measures. In addition to the 26% slowing on CDR-SB, Biogen reported a 42% slowing on ADAS-Cog13, a 50% slowing on the Mini-Mental State Examination, a 30% slowing on the modified Integrated Alzheimer’s Disease Rating Scale and a 23% slowing on ADCOMS. Many of these comparisons were nominally statistically significant, although the study was not designed to establish registrational proof across every secondary endpoint.

Biomarker results were also supportive. Diranersen reduced cerebrospinal-fluid total tau by approximately 50% to 65%, while a tau PET substudy involving 131 patients showed reductions in tau pathology across evaluated brain regions. Biogen characterized diranersen as the first tau-directed therapy to demonstrate reductions in both cerebrospinal-fluid total tau and brain tau pathology in a Phase 2 study.

The important limitation is that the trial did not show separation from placebo on the ADCS-ADL-MCI measure of daily functioning. Biomarker improvement is scientifically valuable, but investors will ultimately require evidence that tau reduction produces consistent and meaningful benefits in patients’ cognition and everyday lives.

Why does the missing dose response create uncertainty for Biogen’s Phase 3 strategy?

Dose-response consistency helps researchers determine whether a drug’s effect is biologically credible and whether the chosen dose can be carried into a pivotal trial with confidence. CELIA produced the opposite of a straightforward pattern: the lowest tested dose delivered the largest apparent clinical benefit, while more frequent or higher dosing did not improve the outcome.

That does not automatically invalidate the 60 mg result. Neurological therapies can have nonlinear dose-response curves, and excessive target suppression does not always generate greater efficacy. Nevertheless, the 60 mg group included only about 60 patients, compared with approximately 115 patients in each higher-dose group and 115 patients receiving placebo. A Phase 3 program will need to confirm the benefit in a much larger population.

Biogen plans to consult regulators before finalizing its registrational strategy and is targeting Phase 3 initiation in 2027. Investors should look for a clear explanation of the selected dose, the statistical design, the intended primary endpoint and how the study will distinguish a reproducible treatment effect from Phase 2 variability.

Administration is another consideration. Diranersen is delivered intrathecally through a lumbar puncture every three or six months. That schedule may be manageable for a serious progressive disease, but it introduces more complexity than an oral medicine and could affect adoption if competing therapies offer simpler administration.

How much does diranersen matter to Biogen’s wider commercial and pipeline outlook?

Diranersen could become an important long-term growth asset, but Biogen’s valuation does not depend on this program alone. The company already has commercial franchises in multiple sclerosis, spinal muscular atrophy, depression, rare diseases and Alzheimer’s disease. It also shares in the economics of Leqembi, the anti-amyloid Alzheimer’s treatment developed with Eisai.

Biogen reported first-quarter 2026 revenue of approximately US$2.48 billion, an increase of 2% from the prior-year period. Non-GAAP diluted earnings reached US$3.57 per share, up 18%, while revenue from the company’s growth products increased 12%. Global Leqembi sales reached US$168 million, representing 74% year-over-year growth.

The challenge is that Biogen’s established multiple-sclerosis portfolio continues to face declining revenue and competitive pressure. Management expects that weakness to weigh on total 2026 revenue even as Leqembi and newer products expand. Diranersen therefore matters because it could extend Biogen’s Alzheimer’s franchise beyond amyloid therapies, but it is still several years away from possible commercialization.

Biogen’s May acquisition of Apellis Pharmaceuticals also changed the portfolio. The transaction added Empaveli and Syfovre, which together produced approximately US$689 million in 2025 net product revenue. Their performance and integration now matter alongside Leqembi, the legacy portfolio and the company’s clinical pipeline.

Does Biogen’s valuation compensate investors for clinical and balance-sheet uncertainty?

At US$191.95 per share, Biogen has a market capitalization of approximately US$28.5 billion and trades at roughly 20.6 times trailing earnings. Based on the midpoint of management’s current 2026 adjusted earnings guidance of US$14.25 to US$15.25 per share, the stock trades near 13 times projected adjusted earnings. That guidance could change when Biogen reports its second-quarter results.

The valuation is not unusually demanding for a profitable biotechnology company with multiple commercial products. However, the apparent discount reflects continuing erosion in the multiple-sclerosis business, uncertainty surrounding new-product growth and the probability that several pipeline investments will not produce approved medicines.

Biogen finished the first quarter with approximately US$4.7 billion in cash and equivalents, US$6.3 billion in total debt and about US$594 million in quarterly free cash flow. Those figures predate the Apellis acquisition. Biogen subsequently used approximately US$3.6 billion of cash and marketable securities and drew US$2.0 billion in term loans to help finance the transaction.

The acquisition materially increased leverage and reduced Biogen’s available cash. It does not create an immediate liquidity crisis, but it reduces the margin for weak execution. The July 29 report should provide the first comprehensive view of Biogen’s post-acquisition balance sheet, updated earnings expectations and debt-management priorities.

What evidence on July 29 and beyond would strengthen or weaken the Biogen investment case?

The July 29 earnings report is the most immediate test. Stable guidance, continued Leqembi adoption, resilient free cash flow and a credible Apellis integration plan would show that Biogen’s operating business can support its pipeline investments and higher debt load. A clear account of Syfovre and Empaveli performance would also help investors assess whether the acquisition can offset pressure in the legacy portfolio.

For diranersen, the strongest positive development would be a Phase 3 design that regulators accept and that directly tests the 60 mg regimen in a sufficiently large population. Longer-term CELIA follow-up showing a sustained clinical effect would strengthen confidence further. Evidence that cognitive benefits align with improved daily functioning would be especially important.

The bearish scenario would include weaker financial guidance, slower growth from recently launched products or higher-than-expected post-acquisition leverage. For diranersen, an unclear regulatory path, difficulty explaining the inverse dose response or failure to reproduce the low-dose benefit would materially reduce the program’s value.

The 8.2% sell-off appears proportionate to the new uncertainty rather than proof that diranersen has failed. The study delivered unusually strong tau biomarker evidence and a potentially meaningful clinical signal, but the primary endpoint miss means investors cannot treat the 60 mg result as confirmed. Biogen now needs to convert an encouraging scientific observation into a defensible pivotal-trial strategy.

What are the key takeaways for Biogen investors after the diranersen data sell-off?

• Biogen closed at US$191.95 on July 14, falling 8.2% as investors reacted to the detailed CELIA presentation.
• Diranersen’s 60 mg dose slowed decline on CDR-SB by 26% and produced encouraging results across several cognitive measures.
• The study missed its primary dose-response endpoint because the higher-dose regimens produced weaker clinical results.
• Strong reductions in cerebrospinal-fluid tau and brain tau pathology provide evidence of biological activity, but the trial showed no benefit on its daily-function measure.
• Biogen plans to seek regulatory input before starting a Phase 3 program, currently targeted for 2027.
• The July 29 earnings report will test Leqembi growth, Apellis integration, updated guidance and Biogen’s post-acquisition balance sheet.
• At roughly 13 times the midpoint of current adjusted earnings guidance, Biogen’s valuation reflects substantial uncertainty but leaves room for upside if execution improves.